Yüklüyor......
Semi-random mutagenesis profile of BCR-ABL during imatinib resistance acquirement in K562 cells
Although imatinib is effective in chronic myeloid leukemia treatment, imatinib resistance due to the T315I mutation and/or other mutations is a challenge to be overcome. However, how DNA mutation occurs, particularly the T315I mutation, remains unclear. In the current study, the mutagenesis of BCR-A...
Kaydedildi:
| Yayımlandı: | Mol Med Rep |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
D.A. Spandidos
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5779997/ https://ncbi.nlm.nih.gov/pubmed/29152650 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2017.7835 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|